WallStSmart

AtriCure Inc (ATRC)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

West Pharmaceutical Services Inc generates 484% more annual revenue ($3.33B vs $569.62M). WST leads profitability with a 17.0% profit margin vs 1.9%. WST appears more attractively valued with a PEG of 2.67. WST earns a higher WallStSmart Score of 61/100 (C+).

ATRC

Hold

35

out of 100

Grade: F

Growth: 6.0Profit: 4.0Value: 4.7Quality: 8.5
Piotroski: 5/9Altman Z: 2.17

WST

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 2.7Quality: 8.5
Piotroski: 4/9Altman Z: 4.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ATRCUndervalued (+56.0%)

Margin of Safety

+56.0%

Fair Value

$74.75

Current Price

$54.54

$20.21 discount

UndervaluedFair: $74.75Overvalued
WSTSignificantly Overvalued (-46.2%)

Margin of Safety

-46.2%

Fair Value

$168.33

Current Price

$346.23

$177.90 premium

UndervaluedFair: $168.33Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ATRC1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.149/10

Conservative balance sheet, low leverage

WST3 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.7310/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Operating MarginProfitability
22.5%8/10

Strong operational efficiency at 22.5%

Areas to Watch

ATRC4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
1.9%3/10

1.9% margin — thin

PEG RatioValuation
10.002/10

Expensive relative to growth rate

P/E RatioValuation
255.9x2/10

Premium valuation, high expectations priced in

WST3 concerns · Avg: 2.7/10
Price/BookValuation
8.2x4/10

Trading at 8.2x book value

PEG RatioValuation
2.672/10

Expensive relative to growth rate

P/E RatioValuation
43.5x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : ATRC

The strongest argument for ATRC centers on Debt/Equity. Revenue growth of 12.8% demonstrates continued momentum.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Debt/Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 22.5%. Revenue growth of 13.8% demonstrates continued momentum.

Bear Case : ATRC

The primary concerns for ATRC are EPS Growth, Profit Margin, PEG Ratio. A P/E of 255.9x leaves little room for execution misses. Thin 1.9% margins leave little buffer for downturns.

Bear Case : WST

The primary concerns for WST are Price/Book, PEG Ratio, P/E Ratio. A P/E of 43.5x leaves little room for execution misses.

Key Dynamics to Monitor

ATRC profiles as a value stock while WST is a mature play — different risk/reward profiles.

ATRC carries more volatility with a beta of 1.26 — expect wider price swings.

WST is growing revenue faster at 13.8% — sustainability is the question.

WST generates stronger free cash flow (81M), providing more financial flexibility.

Bottom Line

WST scores higher overall (61/100 vs 35/100), backed by strong 17.0% margins and 13.8% revenue growth. ATRC offers better value entry with a 56.0% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AtriCure Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. The company is headquartered in Mason, Ohio.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?